/
Other
Tenofovir
10
Pipeline Programs↗
3
Active Trials↗
6
Companies Involved↗
Tenofovir is an early-stage landscape with 10 programs across 6 companies. The most active players are Gilead. 8 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 1
No programs
Phase 2
No programs
Approved
No programs
Analysis
Trial Status
95
clinical trials
Completed77 · 81%
Unknown status8 · 8%
Terminated5 · 5%
Withdrawn2 · 2%
Active, not recruiting2 · 2%
Not yet recruiting1 · 1%
Clinical Trials
Trial Activity
95 trials
A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally
Completed·—·Phase 1·NCT01575405·13 enrolled
Tenofovir Abacavir Platelet Activation Study
Completed·—·Phase 4·NCT02093585·43 enrolled
Page 1 of 7
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)